Payment overview · 2025
General Payments
$311.90
14 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Busch, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SAGINAW, MI · NPI 1235680331
Verified facts
What the public records show
CMS Open Payments records show Michael Busch, NP received $311.90 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Shingrix, Trelegy Ellipta.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.39 | 24.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.92 | 15.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.83 | 13.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.58 | 12.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.11 | 11.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.65 | 8.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.50 | 5.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.49 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.90 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.92 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $36.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 140 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 308 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 92 |
| Lisinopril | Lisinopril | 259 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 60 |
| Metformin Hcl | Metformin Hcl | 223 | 59 |
| Omeprazole | Omeprazole | 201 | 61 |
| Gabapentin | Gabapentin | 153 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 46 |
| Potassium Chloride | Potassium Chloride | 148 | 44 |
| Trulicity | Dulaglutide | 144 | 28 |
| Furosemide | Furosemide | 132 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 52 |
| Farxiga | Dapagliflozin Propanediol | 116 | 24 |
| Tramadol Hcl | Tramadol Hcl | 115 | 20 |
| Baclofen | Baclofen | 113 | 33 |
| Losartan Potassium | Losartan Potassium | 106 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 37 |
| Ibuprofen | Ibuprofen | 96 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 29 |
| Trazodone Hcl | Trazodone Hcl | 84 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 23 |
| Famotidine | Famotidine | 79 | 33 |
| Eliquis | Apixaban | 75 | 25 |
| Pregabalin | Pregabalin | 73 | 19 |
| Metformin Hcl Er | Metformin Hcl | 70 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 11 |
| Chlorthalidone | Chlorthalidone | 68 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 24 |
| Montelukast Sodium | Montelukast Sodium | 62 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 21 |
| Ozempic | Semaglutide | 59 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 21 |
| Topiramate | Topiramate | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 18 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | 16 |
| Buspirone Hcl | Buspirone Hcl | 52 | 17 |
| Carvedilol | Carvedilol | 52 | 19 |
| Sertraline Hcl | Sertraline Hcl | 51 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 16 |
| Jardiance | Empagliflozin | 38 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Prednisone | Prednisone | 30 | 17 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Atenolol | Atenolol | 26 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Meloxicam | Meloxicam | 25 | 13 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | 11 |
| Ezetimibe | Ezetimibe | 23 | 12 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | 11 |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.90 · 14 records | GlaxoSmithKline, LLC. | BEXSERO, GVOKE HYPOPEN, INVEGA SUSTENNA, Kerendia, Korlym, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error